Caliway
Taipei
About Caliway
Caliway is a clinical-stage biotech firm that focuses on small-molecule therapeutics for aesthetic medicine and inflammatory diseases. Caliway's leading candidate, CBL-514, is a lipolysis injectable in Phase II targeting localized fat reduction, cellulite, and Dercum’s disease. The company also develops preclinical programs for obesity, skin aging, and hyperpigmentation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $97.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: tpe:6919
- Website: caliway.com.tw
- Phone: +886-2-2697-1355
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/caliway-3374 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.